



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

	e Application of: David B. Weiner, J. Kim, Donghui Zhang				
Seria	al No.: 09/680,690 Group Art Unit: 1632				
Filin	g Date: October 6, 2000 Examiner: Q. Li				
For:	CELL TARGETING COMPOSITIONS AND METHODS OF USING THE SAME EL531173407US EXPRESS MAIL LABEL NO: EL531173407US DATE OF DEPOSIT: February 1, 2002				
Box	□ NON-FEE				
	\square AF				
	tant Commissioner for Patents ington DC 20231				
Sir:					
	AMENDMENT TRANSMITTAL LETTER				
	Transmitted herewith for filing in the above-identified patent application is:				
	A Preliminary Amendment.				
\boxtimes	A Reply to the Office Action Dated November 5, 2001.				
□ '	An Amendment Supplemental to the Paper filed				
	Other:				
\boxtimes	Applicant(s) has previously claimed small entity status under 37 CFR §1.27.				

DUC	KEI NO.: UPN-3900 -2- FAIEN	1					
	Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR §1.27 as:						
	an Independent Inventor						
	a Small Business Concern						
	a Nonprofit Organization						
	This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.						
	Substitute Pages of the Specification are enclosed.						
	An Abstract is enclosed.						
	Sheets of Proposed Corrected Drawings are enclosed.						
	A Certified Copy of each of the following applications: is enclosed.						
	An Associate Power of Attorney is enclosed.						
	Information Disclosure Statement.						
	Attached Form 1449.						
	A copy of each reference as listed on the attached Form PTO-1449 is enclose herewith.	d					
	Appended Material as follows:						
	Other Material as follows:						

ì

DOCKET NO.: UPN-3906 - 3 - PATENT

FEE CALCULATION

No Additional Fee is Due.

*****			*****	SMALL	ENTITY	NOT SMAL	L ENTITY
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	31	31 (20 MINIMUM)	0	\$9 EACH	\$0	\$18 EACH	\$
INDEP. CLAIMS	7	7 (3 MINIMUM)	0	\$42 EACH	\$0	\$84 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$140	\$0	\$280	\$
☐ ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$
TWO MONTH EXTENSION OF TIME				\$200	\$200	\$400	\$
☐ THREE MONTH EXTENSION OF TIME				\$460	\$;	\$920	\$
☐ FOUR MONTH EXTENSION OF TIME				\$720	\$	\$1440	\$
☐ FIVE MONTH EXTENSION OF TIME				\$980	\$	\$1960	\$
☐ LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$)
☐ TERMINAL DISCLAIMER				\$55	\$	\$110	\$
☐ OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE					\$200		\$

- A Check is Enclosed in the Foregoing Amount Due.
- Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of November 5, 2001 to and through February 5, 2002 comprising an extension of the shortened statutory period of two (2) month(s).
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

DOCKET NO.: UPN-3906

- 4 -

PATENT

XI	The Commissioner is authorized to charge payment of the following fees and to						
	d any overpayment associated with this communication or during the pendency s application to deposit account 23-3050. This sheet is provided in duplicate.						
		The Foregoing Amount Due for Filing this Paper.					
		Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.					
		Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).					

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: Februar 1, 2002

Mark DeLuca

Registration No. 33,229

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2001 WW



TEXT CENTER 1600/290

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David B. Weiner et al.

Serial No.: 09/680,690

Group Art Unit: 1632

Filed: October 6, 2000

Examiner: Li, Q.

For:

CELL TARGETING COMPOSITIONS AND METHODS OF USING THE

SAME

EXPRESS MAIL LABEL NO: EL531173407US

DATE OF DEPOSIT: February 1, 2002

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

REPLY

This reply is being filed in response to the Official Action dated November 5, 2001 for the above-identified patent application. The period to respond is extended by petition and payment of the appropriate fee provided herewith.

Claims 1-31 are in the application.

Claims 1-31 have been subject to a requirement for restriction.

Applicants provisionally elect Group I, claims 1-6 and 8-13, wherein the compound is a nucleic acid. This election is made with traverse.

Applicants respectfully point out that claim 1 is a generic claim directed at methods of delivering compounds to cells that express costimulatory molecules and is not limited to the two subgenuses, nucleic acids and proteins, for which the requirement for restriction has been made. Applicants urge that an election of species may have been appropriate. However, because claim 1 is a generic claim that embraces both groups identified by the Examiner as well as additional subject matter, the requirement for restriction should be reconsidered and withdrawn. If the requirement for

DOCKET NO.: UPN-3906 PATENT APPLICATION

SERIAL NO.: 09/680,690 FILED: OCTOBER 6, 2000

restriction is withdrawn and election of species is required, Applicants elect the nucleic acid as the elected species.

In the event that the requirement for restriction is maintained, Applicants elect Group I, claims 1-6 and 8-13, wherein the compound is a nucleic acid.

Applicants respectfully request that claims 1-31 be examined and allowed at this time.

Respectfully submitted,

Mark DeLuca

Registration No. 33,229

Date: (e b 1, 2002

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 (215) 568-3100